NEW YORK--(BUSINESS WIRE)--IRIS by Real Chemistry today released its second market-view report, “From Cost to Value: The Economic Impacts of GLP-1 Agonists on U.S. Healthcare.” The immersive report highlights the growing economic impacts of obesity and the GLP-1 agonist market on the U.S. healthcare system.

纽约--（商业新闻短讯）--Real Chemistry的IRIS今天发布了第二份市场观点报告，“从成本到价值：GLP-1激动剂对美国医疗保健的经济影响”。这份沉浸式报告强调了肥胖和GLP-1激动剂市场对美国医疗保健系统日益增长的经济影响。

The forecast predicts that the increase in uptake of these medicines will require the U.S. healthcare system to develop innovative financial models to treat obesity over the short and long-term..

该预测预测，这些药物摄入量的增加将要求美国医疗保健系统开发创新的金融模式，以在短期和长期内治疗肥胖症。。

“From groundbreaking consumer demand to the emergence of medical spas and online providers, the forces that are driving the U.S. obesity and GLP-1 agonist market are creating challenges for industry stakeholders that are coming from both within and outside of the healthcare system,” said Rita Glaze-Rowe, President of Transformative Healthcare Markets at Real Chemistry.

“从突破性的消费者需求到医疗水疗和在线提供商的出现，推动美国肥胖和GLP-1激动剂市场的力量正在为来自医疗系统内外的行业利益相关者带来挑战，”Real Chemistry变革医疗市场总裁丽塔·格拉斯·罗（Rita Glaze Rowe）说。

“As obesity continues to impact nearly 70% of the American population according to the CDC, understanding the treatment options for this disease and the economic implications of this market are crucial as we all work toward sustainable patient outcomes.”.

。

The report reveals the concerning trend of consumers purchasing GLP-1 agonists through a “gray market,” consisting of online providers and medical spas. While these entities offer the coveted medicines at presumable lower costs and added convenience, IRIS reveals that consumers often pay higher costs for these obesity treatments than if they received them through their healthcare providers as covered by health insurance..

该报告揭示了消费者通过由在线提供商和医疗SPA组成的“灰色市场”购买GLP-1激动剂的令人担忧的趋势。虽然这些实体以可能更低的成本提供令人垂涎的药物，并增加了便利性，但IRIS揭示，与通过健康保险覆盖的医疗保健提供者接受治疗相比，消费者通常为这些肥胖治疗支付更高的成本。。

Additional findings from the report include:

报告的其他发现包括：

The use of online providers, compound pharmacies and medical spas continues to increase, leading to commercially insured consumers, in some cases, paying two or three times more compared to traditional healthcare provider engagement and reimbursement.

在线提供商、复合药店和医疗SPA的使用继续增加，导致商业保险消费者在某些情况下比传统医疗保健提供商的参与和报销多付两到三倍。

This creates “blind spots” for healthcare stakeholders and industry professionals due to lack of data visibility (e.g., claims) and aggregated reporting.

由于缺乏数据可见性（例如索赔）和汇总报告，这为医疗保健利益相关者和行业专业人员创造了“盲点”。

Polarizing coverage decisions have occurred as insurers/employers and policymakers grapple with the perceived cost of GLP-1 agonists in treating obesity. However, the real question should be, “Can we afford not to cover?” The IRIS budget impact model found that costs for non-treatment of obesity could exceed the cost to treat by as much as $31.47 billion in the coming years..

随着保险公司/雇主和政策制定者努力解决GLP-1激动剂治疗肥胖症的感知成本，发生了两极分化的保险决策。然而，真正的问题应该是，“我们能负担不起吗？”IRIS预算影响模型发现，未来几年，不治疗肥胖的成本可能超过治疗成本高达314.7亿美元。。

IRIS analysis found that more than 80% of claims for GLP-1 medicines are ultimately approved by insurers. This is in stark contrast to the public perception that commercial insurance is severely restricting or will not cover GLP-1 agonists indicated for obesity. IRIS has observed improving access trends and approval rates among individuals who are commercially insured..

IRIS分析发现，超过80%的GLP-1药物索赔最终得到了保险公司的批准。这与公众的看法形成鲜明对比，即商业保险严重限制或不涵盖肥胖所指示的GLP-1激动剂。IRIS观察到，商业保险个人的准入趋势和批准率有所提高。。

“We have seen that costs associated with GLP-1 agonists are continuing to rise, and cost-based decisions are being made by public and private insurers, as well as employers as utilization increases and organizations work to manage or contain costs,” added Glaze-Rowe. “But there are many variables involved that we can’t see or track via claims data and traditional reporting mechanisms.

“我们已经看到，与GLP-1激动剂相关的成本持续上升，随着利用率的提高和组织努力管理或控制成本，公共和私人保险公司以及雇主正在做出基于成本的决策，”Glaze Rowe补充道。“但其中涉及许多我们无法通过索赔数据和传统报告机制看到或跟踪的变量。

It is important to acknowledge and begin to plan for more integrated value metrics within this market as the potential population health benefits will require a new lens and integrated value frameworks.”.

。

The report calls for healthcare policymakers and consumers to recognize the vulnerabilities introduced by the emerging “gray market” and promotes informed decision-making between consumers and their physicians, as well as appropriate management of medicines and behavior changes. The visibility and evidence generation that will be derived from this approach will benefit all healthcare leaders in improving overall health and reaching a more cost-effective state for GLP-1 agonists within the obesity market..

该报告呼吁医疗保健政策制定者和消费者认识到新兴“灰色市场”带来的脆弱性，并促进消费者与其医生之间的明智决策，以及对药物和行为改变的适当管理。从这种方法中获得的可见性和证据生成将有助于所有医疗保健领导者改善整体健康状况，并在肥胖市场中达到GLP-1激动剂更具成本效益的状态。。

IRIS by Real Chemistry is an insights-as-a-service platform providing U.S. market-level intelligence for the obesity market. The platform launched in April 2024 and is tracking seven distinct dimensions of the U.S. obesity market (inclusive of all anti-obesity medicines). Leveraging AI, Real Chemistry’s billions of proprietary data points, and expert analysis, IRIS delivers immersive intelligence to help business leaders navigate transformative market events and innovations.

Real Chemistry的IRIS是一个insights-as-a-service平台，为肥胖市场提供美国市场层面的情报。该平台于2024年4月推出，正在跟踪美国肥胖市场的七个不同层面（包括所有抗肥胖药物）。利用人工智能、Real Chemistry的数十亿专有数据点和专家分析，IRIS提供身临其境的智能，帮助企业领导者驾驭变革性的市场事件和创新。

IRIS is available through an annual licensed dashboard, market-view reports produced every other month, and other formats in near real-time..

IRIS可通过年度授权仪表板、每隔一个月生成的市场视图报告以及其他近实时格式获得。。

The report’s insights were generated through a methodology that included systematic literature reviews, qualitative stakeholder interviews and development of a budget-impact model to benchmark current and future cost implications for the U.S. obesity market.

该报告的见解是通过一种方法产生的，该方法包括系统的文献综述，定性的利益相关者访谈以及开发预算影响模型，以衡量美国肥胖市场当前和未来的成本影响。

About IRIS by Real Chemistry

关于真实化学的IRIS

The platform, reports and associated website page(s) are intended for U.S. audiences and organizations with operations in the U.S. The analysis is conducted by Real Chemistry subject matter experts and is independent and not representative of or sponsored by clients. Visit www.realchemistry.com/transformative-healthcare-markets for more information..

该平台、报告和相关网站页面面向美国观众和在美国运营的组织。分析由真正的化学主题专家进行，是独立的，不代表客户或由客户赞助。有关更多信息，请访问www.realchemistry.com/transformative-healthcare-markets。。

About Real Chemistry

关于真实化学

Real Chemistry is a trusted partner to the world’s most successful life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, we help the healthcare industry better understand, reach and engage patients and professionals using bold ideas to create human-centric healthcare experiences.

。作为人工智能支持的受众分析和见解的领先提供商，我们帮助医疗保健行业更好地理解、接触和吸引患者和专业人员，使用大胆的想法创造以人为中心的医疗保健体验。

Anchored by our culture of innovation and boundless creativity, our 2,000+ experts across the life sciences, marketing communications and technology enable modern medical therapies and those they were designed to help, meet and exceed their potential..

在我们的创新文化和无限创造力的支撑下，我们拥有2000多名生命科学、营销传播和技术方面的专家，能够帮助现代医学疗法以及那些旨在帮助、满足和超越其潜力的疗法。。